top of page

Our Team


Emre Koyuncu.png

Emre Koyuncu, Ph.D., Founder and CEO

Dr. Koyuncu is a molecular biologist & virologist who has more than 15 years of experience in drug discovery.  The intellectual property he developed while he was working at Princeton University formed the basis of several successful startups including Kadmon (acquired by Sanofi) and was licensed/optioned by companies including Merck. Prior to founding Crescenta, Dr. Koyuncu served as a Co-founder and Head of Biology at Evrys Bio. He received his PhD from Heinrich-Pette-Institute for Experimental Virology and Immunology, Hamburg, Germany and was a post-doctoral fellow at Princeton University.

Hahn Kim.png

Hahn Kim, Ph.D. , Founder, Chemistry

Dr. Kim has a deep expertise in the area of discovery chemistry. He is currently serving as the founding director of Small Molecule Screening Center at Princeton University. Prior to founding Crescenta, he served as a co-founder and acting Chief Scientific Officer of Chiromics, a Princeton start-up that developed novel chemical technologies for drug discovery and played an instrumental role in establishing the company’s successful research collaborations with companies such as BMS, Genentech, GSK, Merck, and Pfizer. Dr. Kim received his Ph.D. from Princeton University, where he also was a NIH/NCI post-doctoral fellow.

Daniel V. Maravei, Ph.D., Chief Business Officer

 Dr. Maravei is a seasoned business development leader with a strong scientific background and 20 years of experience in the biotech industry. He has a track record of successful deals and partnerships across multiple therapeutic areas and modalities. Most recently, he served as Senior Director and Head of Business Development at Viacyte where he led corporate development initiatives prior to the company’s acquisition by Vertex. Prior to Viacyte, Daniel was a Managing Director and Analyst at MBH Investments, a biotechnology-focused healthcare fund. Prior to MBH, Daniel held business development roles with increasing responsibility at Incyte where he led partnering discussions for the company’s Jak2 franchise in Oncology prior to the commercial launch of Jakafi. Daniel holds a PhD in Cellular and Molecular Biology from Boston University School of Medicine and an MBA in Finance from The University of Chicago Booth School of Business.

Scientific Advisory Board

Gokhan Hotamisligil.png

Gökhan Hotamışlıgil, M.D., Ph.D., Chair

Dr. Hotamışlıgil is the J.S. Simmons Professor of Genetics and Metabolism and the Director of the Center for Metabolic Research at Harvard T.H. Chan School of Public Health. He is an internationally recognized leader. His discoveries on metabolism and immune regulation have played a pioneering role in the emergence of immunometabolism as a new field and identified central mechanisms of metabolic diseases. Most recently, he received the 2018 EASD–Novo Nordisk Foundation Diabetes Prize for Excellence in recognition of his exceptional contributions, which have opened up potential avenues for treatment of many metabolic diseases.

Patrick Lam.png

Patrick Y. Lam, Ph.D.

Dr. Lam is a Distinguished Professor of Medicinal Chemistry at Baruch S. Blumberg Institute, who has over 30 years of experience in drug discovery. During his tenure at BMS, he was responsible for the discovery of Eliquis®/Apixaban, a blockbuster anticoagulant drug generating over $10 billion in annual sales. For this achievement, he and his team was honored with the 2015 American Chemical Society Heroes of Chemistry Award. He is also internationally recognized as the co-discoverer of the powerful Chan-Lam Coupling Reaction.

Greg Cosma.png

Greg Cosma, Ph.D.

Dr. Cosma is a renowned toxicologist and thought leader in the pharmaceutical industry amassing over 25 years of experience. At Genentech, his most recent role was Vice President of Research and Early Development, where he led their safety assessment organization and also chaired the Genentech Development Review Committee (DRC), guiding the preclinical development of their pipeline through first-in-human studies. His leadership across R&D has led to the approval of many drugs now on the market.

Lynn Enquist.png

Lynn Enquist, Ph.D.

Dr. Enquist is Henry L. Hillman Professor in Molecular Biology, Emeritus at Princeton University and Princeton Neuroscience Institute. He is a distinguished leader in the fields of molecular biology and virology. He has years of research, business and management experience in academia, government, biotech and large pharmaceutical companies including DuPont and DuPont-Merck.

Board of Directors

bottom of page